Who is sponsoring NCT05062291?

NCT05062291 is sponsored by Merit Medical Systems, Inc..

What drugs are being tested in NCT05062291?

Interventions in NCT05062291: Merit WRAPSODY Endovascular Stent Graft.

What condition does NCT05062291 study?

NCT05062291 studies Venous Stenosis, Venous Occlusion.

Is NCT05062291 still recruiting?

NCT05062291 is currently active, enrolled. Last updated 10 December 2025.

Last reviewed 2025-12-10 · How we verify

NCT05062291

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)

Active, enrolled Last updated 10 December 2025

What this trial tests

trial testing Merit WRAPSODY Endovascular Stent Graft in Venous Stenosis in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 June 2022

Primary endpoint
15 April 2026

15 October 2027

Quick facts

Lead sponsor	Merit Medical Systems, Inc.
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	500
Start date	23 June 2022
Primary completion	15 April 2026
Estimated completion	15 October 2027
Sites	35 locations across New Zealand, Netherlands, Greece, United Kingdom, Israel, Germany, Australia, Portugal

Drugs / interventions tested

Merit WRAPSODY Endovascular Stent Graft

Conditions studied

Venous Stenosis — all drugs for Venous Stenosis →
Venous Occlusion — all drugs for Venous Occlusion →

Sponsor

Merit Medical Systems, Inc.

Who can join

18 and older, any sex, with Venous Stenosis or Venous Occlusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The WRAP Study aims to expand and understand the safety and efficacy data on the WRAPSODY Endoprosthesis System in a real-world population.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective, Multicenter, Observational Study to Evaluate a Cell-Impermeable Endoprosthesis for Treatment of Stenosis or Occlusion within the Dialysis Outflow Circuit of an Arteriovenous (AV) Fistula or AV Graft (The WRAP Registry).
Rajan DK, Kitrou PM. · · 2023 · PMID 37592020 · DOI 10.1007/s00270-023-03531-w

Verify or expand the search:

Other Merit Medical Systems, Inc. trials

Trials by the same sponsor.

NCT06422871 — PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis · recruiting
NCT05307783 — EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging · completed
NCT04815291 — Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc ) · NA · terminated
NCT05050799 — US Post-Market Surveillance Study of the Surfacer System · recruiting
NCT03644017 — The Merit WRAPSODY™ Endovascular Stent Graft · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05062291 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merit Medical Systems, Inc.
Last refreshed: 10 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05062291.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing